Report period | 2019 | 2020 | 2021 | 2022 | 2023 | Q2 24 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
TECH:US | Bio-Techne | Common share | - | US09073M1045 | $76.42 |
Company name | Bio-Techne |
---|---|
Tags | #biotechnology, #s&p500 index |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | 614 McKinley Place NE Minneapolis, MN 55413 United States |
Mailing address | 614 McKinley Place NE Minneapolis, MN 55413 United States |
Website | investors.bio-techne.com |
Information disclosure | www.sec.gov |